Back to search

Article

Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines

2024-04-12

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Next-generation pneumococcal vaccines currently in clinical trials include 24- and 31-valent pneumococcal conjugate vaccines (PCV24, PCV31), which aim to prevent upper-respiratory carriage and disease involving the targeted serotypes. We aimed to estimate the comprehensive health-economic burden associated with acute respiratory infections (ARIs) and invasive pneumococcal dise...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4808fcc7-d9f9-553b-bef8-9bfec515c51e
DOI
10.1101/2024.04.11.24305684
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccinesDOI 10.1101/2024.04.11.24305684
Cost-Effectiveness Analysis of Pneumococcal Vaccine in the Pediatric Population: A Systematic ReviewSemantic proximity
A model-based evaluation of the cost-effectiveness of paediatric and elderly vaccination against pneumococcal infection in EnglandSemantic proximity
Pneumococcal Diseases Caused by Serotype Replacement in Colombia: A Cost-Effectiveness Analysis of Pneumococcal Conjugate Vaccines in Infants and Its Herd Protection in Older AdultsSemantic proximity
Pneumococcal meningitis in adults in 2014-2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan.Semantic proximity
Pneumococcal Meningitis in Adults in 2014-2018 After Introduction of Pediatric 13-valent Pneumococcal Conjugate Vaccine in JapanSemantic proximity
Serotype-specific pneumococcal invasiveness: a global meta-analysis of paired estimates of disease incidence and carriage prevalenceSemantic proximity
Incidence rates, emerging serotypes and genotypes, and antimicrobial susceptibility of pneumococcal disease in Taiwan: A multi-center clinical microbiological study after PCV13 implementation.Semantic proximity
Optimizing the timing of one or two doses of pneumococcal conjugate vaccines in older adults in the United States: a modeling studySemantic proximity
Parapneumonic effusions related to<i>Streptococcus pneumoniae</i>: serotype and disease severity trends from 2006 to 2018 in Bristol, UKSemantic proximity
Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valencySemantic proximity
Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infectionsSemantic proximity
Serotype epidemiology and case-fatality risk of invasive pneumococcal disease: a nationwide population study from Switzerland, 2012–2022Semantic proximity
Select a neighboring publication to make it the new centre.